1.Niedermaier S, Hilgendorff A: Bronchopulmonary dysplasia - an overview about pathophysiologic concepts. Mol Cell Pediatr 2015, 2(1):2.
2.Bassler D: Inhalation or instillation of steroids for the prevention of bronchopulmonary dysplasia. NEONATOLOGY 2015, 107(4):358–359.
3.Gentner S, Laube M, Uhlig U, Yang Y, Fuchs HW, Dreyhaupt J, Hummler HD, Uhlig S, Thome UH: Inflammatory Mediators in Tracheal Aspirates of Preterm Infants Participating in a Randomized Trial of Permissive Hypercapnia. FRONT PEDIATR 2017, 5:246.
4.Gupta S, Prasanth K, Chen CM, Yeh TF: Postnatal corticosteroids for prevention and treatment of chronic lung disease in the preterm newborn. Int J Pediatr 2012, 2012:315642.
5.Ji FJ, Yin Y, Xu J, Zhao LX, Zhou YJ, Zhu L: [Early postnatal application of glucocorticoids for preventing bronchopulmonary dysplasia in preterm infants: a Meta analysis]. Zhongguo Dang Dai Er Ke Za Zhi 2017, 19(6):638–645.
6.Zeng L, Tian J, Song F, Li W, Jiang L, Gui G, Zhang Y, Ge L, Shi J, Sun X et al: Corticosteroids for the prevention of bronchopulmonary dysplasia in preterm infants: a network meta-analysis. Arch Dis Child Fetal Neonatal Ed 2018.
7.Lister P, Iles R, Shaw B, Ducharme F: Inhaled steroids for neonatal chronic lung disease. Cochrane Database Syst Rev 2000(3):D2311.
8.Ke H, Li ZK, Yu XP, Guo JZ: [Efficacy of different preparations of budesonide combined with pulmonary surfactant in the treatment of neonatal respiratory distress syndrome: a comparative analysis]. Zhongguo Dang Dai Er Ke Za Zhi 2016, 18(5):400–404.
9.Bassler D, Shinwell ES, Hallman M, Jarreau PH, Plavka R, Carnielli V, Meisner C, Engel C, Koch A, Kreutzer K et al: Long-Term Effects of Inhaled Budesonide for Bronchopulmonary Dysplasia. N Engl J Med 2018, 378(2):148–157.
10.Onland W, Offringa M, van Kaam A: Late (>/ = 7 days) inhalation corticosteroids to reduce bronchopulmonary dysplasia in preterm infants. Cochrane Database Syst Rev 2017, 8:D2311.
11.Shah VS, Ohlsson A, Halliday HL, Dunn M: Early administration of inhaled corticosteroids for preventing chronic lung disease in very low birth weight preterm neonates. Cochrane Database Syst Rev 2017, 1:D1969.
12.Cole CH, Colton T, Shah BL, Abbasi S, MacKinnon BL, Demissie S, Frantz IR: Early inhaled glucocorticoid therapy to prevent bronchopulmonary dysplasia. N Engl J Med 1999, 340(13):1005–1010.
13.Lefebvre C, Eric M, Glanville J: Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.0.2 [updated September 2009]: The Cochrane Collaboration, 2009. Available from www.cochrane-handbook.org.
14.Higgins JPT ADSJ: Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]: The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
15.Higgins JP, Thompson SG: Quantifying heterogeneity in a meta-analysis. STAT MED 2002, 21(11):1539–1558.
16.Kovacs L, Davis GM, Faucher D, Papageorgiou A: Efficacy of sequential early systemic and inhaled corticosteroid therapy in the prevention of chronic lung disease of prematurity. ACTA PAEDIATR 1998, 87(7):792–798.
17.Merz U, Kusenbach G, Hausler M, Peschgens T, Hornchen H: Inhaled budesonide in ventilator-dependent preterm infants: a randomized, double-blind pilot study. Biol Neonate 1999, 75(1):46–53.
18.Jonsson B, Eriksson M, Soder O, Broberger U, Lagercrantz H: Budesonide delivered by dosimetric jet nebulization to preterm very low birthweight infants at high risk for development of chronic lung disease. ACTA PAEDIATR 2000, 89(12):1449–1455.
19.Yeh TF, Lin HC, Chang CH, Wu TS, Su BH, Li TC, Pyati S, Tsai CH: Early intratracheal instillation of budesonide using surfactant as a vehicle to prevent chronic lung disease in preterm infants: a pilot study. PEDIATRICS 2008, 121(5):e1310-e1318.
20.Bassler D, Plavka R, Shinwell ES, Hallman M, Jarreau PH, Carnielli V, Van den Anker JN, Meisner C, Engel C, Schwab M et al: Early Inhaled Budesonide for the Prevention of Bronchopulmonary Dysplasia. N Engl J Med 2015, 373(16):1497–1506.
21.Yeh TF, Chen CM, Wu SY, Husan Z, Li TC, Hsieh WS, Tsai CH, Lin HC: Intratracheal Administration of Budesonide/Surfactant to Prevent Bronchopulmonary Dysplasia. Am J Respir Crit Care Med 2016, 193(1):86–95.
22.L-J D, H-B P, X-Q G: Effects of budesonide combined with pulmonary surfactant on bronchopulmonary dysplasia in patients with severe respiratory distress syndrome. Chin J Neonatol 2017, 32(5).
23.Yi-jiang C, Shui-tang Z, Run-na Y: Intratracheal administration of budesonide within seven days after birth for preventing bronchopulmonary dysplasia in preterm infants:a systematic review and meta-analysis. Chinese JOurnal of Evidence Based Pediatrics 2016, 11(4):259–264.
24.Niedermaier S HA: Bronchopulmonary dysplasia-an overview about pathophysiologic concepts. Molecular and cellular pediatrics 2015, 2(1):2.
25.Speer CP: Pulmonary inflammation and bronchopulmonary dysplasia. J PERINATOL 2006, 26 Suppl 1:S57-S62, S63-S64.
26.Choi CW, Lee J, Oh JY, Lee SH, Lee HJ, Kim BI: Protective effect of chorioamnionitis on the development of bronchopulmonary dysplasia triggered by postnatal systemic inflammation in neonatal rats. PEDIATR RES 2016, 79(2):287–294.
27.Rostas SE, McPherson C: Systemic Corticosteroids for the Prevention of Bronchopulmonary Dysplasia: Picking the Right Drug for the Right Baby. Neonatal Netw 2016, 35(4):234–239.
28.Shinwell ES, Portnov I, Meerpohl JJ, Karen T, Bassler D: Inhaled Corticosteroids for Bronchopulmonary Dysplasia: A Meta-analysis. PEDIATRICS 2016, 138(6).
29.Kallapur SG, Jobe AH: Contribution of inflammation to lung injury and development. Arch Dis Child Fetal Neonatal Ed 2006, 91(2):F132-F135.
30.Hayes DJ, Feola DJ, Murphy BS, Shook LA, Ballard HO: Pathogenesis of bronchopulmonary dysplasia. RESPIRATION 2010, 79(5):425–436.
31.Aghai ZH, Camacho J, Saslow JG, Mody K, Eydelman R, Bhat V, Stahl G, Pyon K, Bhandari V: Impact of histological chorioamnionitis on tracheal aspirate cytokines in premature infants. Am J Perinatol 2012, 29(7):567–572.
32.TF Y, YJ L, CH L: The effects of early postnatal dexamethasone therapy on pulmonary outcome in premature infants with respiratory distress syndrome: a two‐year follow‐up study. ACTA PAEDIATR 2005, 94:310–316.
33.RF S: Early postnatal dexamethasone therapy for the prevention of chronic lung disease. PEDIATR RES 1999, 45:226A.
34.Li L, Yang C, Feng X, Du Y, Zhang Z, Zhang Y: Effects of intratracheal budesonide during early postnatal life on lung maturity of premature fetal rabbits. Pediatr Pulmonol 2018, 53(1):28–35.
35.Barrette AM, Roberts JK, Chapin C, Egan EA, Segal MR, Oses-Prieto JA, Chand S, Burlingame AL, Ballard PL: Antiinflammatory Effects of Budesonide in Human Fetal Lung. Am J Respir Cell Mol Biol 2016, 55(5):623–632.
36.Kothe TB, Royse E, Kemp MW, Schmidt AF, Salomone F, Saito M, Usuda H, Watanabe S, Musk GC, Jobe AH et al: Effects of budesonide and surfactant in preterm, fetal sheep. Am J Physiol Lung Cell Mol Physiol 2018.
37.Zhang ZQ, Zhong Y, Huang XM, Du LZ: Airway administration of corticosteroids for prevention of bronchopulmonary dysplasia in premature infants: a meta-analysis with trial sequential analysis. BMC PULM MED 2017, 17(1):207.
38.Kelly EN, Shah VS, Levenbach J, Vincer M, DaSilva O, Shah PS: Inhaled and systemic steroid exposure and neurodevelopmental outcome of preterm neonates. J Matern Fetal Neonatal Med 2018, 31(20):2665–2672.
39.Hines D, Modi N, Lee SK, Isayama T, Sjors G, Gagliardi L, Lehtonen L, Vento M, Kusuda S, Bassler D et al: Scoping review shows wide variation in the definitions of bronchopulmonary dysplasia in preterm infants and calls for a consensus. ACTA PAEDIATR 2017, 106(3):366–374.
40.Halliday HL, Patterson CC, Halahakoon CW: A multicenter, randomized open study of early corticosteroid treatment (OSECT) in preterm infants with respiratory illness: comparison of early and late treatment and of dexamethasone and inhaled budesonide. PEDIATRICS 2001, 107(2):232–240.